Sensorion to Participate in ARO 48th Annual Midwinter Meeting

Sensorion, a clinical-stage biotech company based in Montpellier, will participate in the upcoming Association for Research in Otolaryngology (ARO) 48th Annual Midwinter Meeting in Orlando, Florida. The event will take place from February 22-26, 2025. The company focuses on developing therapies for hearing loss and related disorders.

During the conference, Laurent Désiré, Ph.D., Head of Preclinical Development at Sensorion, alongside Professor Christine Petit from the Hearing Institute, will present two posters. These presentations will discuss the novel GJB2-GT gene therapy approach for treating a common subtype of human deafness, DFNB1.

The participation of Sensorion in this meeting highlights its ongoing efforts to advance understanding and treatment options for hearing disorders, targeting genetic causes to benefit both children and adults.